No surprises from Blis first day

The Dunedin-based biotech stock closed its first day on the main board at $1.05 with around $90,000 of shares changing hands.

The move to a main board listing is not expected to make much initial difference to the share price, although it does widen the potential market for shares.

Blis recently told shareholders that it has enough financial resources to fund its activities for the next three years, and hoped to begin earning money from its first Salivaricin B products well within that time frame.

Salivaricin B naturally prevents or controls streptococcal throat infections and comes from a collection of bacteriocin like inhibitory substances, after which the company is named.

It is the first product the company plans to take to commercialisation.

Comments from our readers

No comments yet

Add your comment:

Your name:
Your email:	Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Anti-spam verification:

Type the text you see in the image into the field below. You are asked to do this in order to verify that this enquiry is not being performed by an automated process.

Related News:

BLIS Technologies announces a net deficit of $1,856k for the March 2013 financial year
Blis share price spike
Blis to clean up share register, buying small parcels
Blis K12 probiotic to get ruff ruff test in dogs
BLIS Technology forecasts wider 2013 loss, seeks to raise capital